Literature DB >> 30178827

RBM5-AS1 participates in fracture healing and inhibits apoptosis of bone cells through the up-regulation of β-catenin.

Y-Z Huang1, L Zhao, C-L Wang, S-J Tian, S Liu, J-F Ge.   

Abstract

OBJECTIVE: The aim of this study was to detect the expression of RBM5-AS1 during fracture healing, and to explore its possible mechanism.
MATERIALS AND METHODS: A mice tibia fracture model was constructed in this study. Mice in the control group and experimental group were sham-operated on the left tibia and were operated in the right tibia, respectively. The tibia bones of both groups were obtained at 4 d, 8 d, 12 d, 16 d, 20 d, and 24 d after the operation. Quantitative polymerase chain reaction (qPCR) was used to detect the expression of RBM5-AS1 in tibiae. After interfering with the expression of RBM5-AS1 in bone cells, Cell Counting Kit-8 (CCK-8) was used to detect cell proliferation ability, and flow cytometry was applied to detect apoptosis. Western blot was used to measure the protein expression of beta-catenin and RBM5 after down-regulating RBM5-AS1. Finally, beta-catenin was interfered in osteoblasts to explore the relationship between RBM5-AS1 and beta-catenin.
RESULTS: Compared with the control group, the expression of RBM5-AS1 in the experimental group was significantly increased on the 4 d, 8 d, 12 d, and 16 d after fracture surgery. However, no statistical difference was observed on the 20 d and 24 d between the two groups. After interfering with RBM5-AS1, the apoptosis of chondrocytes and osteoblasts was significantly increased in both mouse and human cells, while the expression of beta-catenin was strikingly decreased. Further up-regulation of beta-catenin could reduce the apoptosis of bone cells. The expression of RBM5, which was a natural antisense transcript of RBM5-AS1, was increased after down-regulating RBM5-AS1.
CONCLUSIONS: RBM5-AS1 can inhibit the apoptosis of bone cells by promoting the expression of beta-catenin and can be used as a biomarker for fracture healing.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178827     DOI: 10.26355/eurrev_201808_15702

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  LncRNA RBM5-AS1 Promotes Osteosarcoma Cell Proliferation, Migration, and Invasion.

Authors:  Biyong Deng; Runsang Pan; Xin Ou; Taizhe Wang; Weiguo Wang; Yingjie Nie; Houping Chen
Journal:  Biomed Res Int       Date:  2021-03-15       Impact factor: 3.411

2.  The function of microRNA-211 expression in post-fracture bone cell apoptosis involving the transforming growth factor-β/ phosphoinositide 3-kinase signaling pathway.

Authors:  Tongxin Sun; Dai Yang; Yuanpeng Wu; Qingang Sheng
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

3.  Hypoxia-induced lncRNA RBM5-AS1 promotes tumorigenesis via activating Wnt/β-catenin signaling in breast cancer.

Authors:  Xinping Li; Jingyan Yang; Ruiqi Ni; Jintian Chen; Yanhao Zhou; Hao Song; Liang Jin; Yi Pan
Journal:  Cell Death Dis       Date:  2022-02-02       Impact factor: 8.469

4.  RBM5-AS1 promotes radioresistance in medulloblastoma through stabilization of SIRT6 protein.

Authors:  Chuanying Zhu; Keke Li; Mawei Jiang; Siyu Chen
Journal:  Acta Neuropathol Commun       Date:  2021-07-05       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.